Ligand Pharmaceuticals Prices $625M Convertible Debt Offering

Ligand Pharmaceuticals has priced a private offering of $625 million in aggregate principal amount of 0.0% convertible senior notes due in 2031. The unsecured, interest-free debt will be used to support the company's operations and strategic initiatives.

By Preeti Singh, SA News Editor · Seeking Alpha · June 23, 2026, 09:27 UTC

Ligand Pharmaceuticals Prices $625M Convertible Debt Offering

Tickers: $LGND

Topics: capital_raising convertible_notes

Read the full article at Seeking Alpha

More World news

Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC